ERBB2 and cancer: TP53 mutations and ERBB2 amplifications were more prevalent (67.2% and 23.4%, respectively) in gastric cancers with CDX2 induction and a parallel induction of HNF4A than in the whole group of cancers with CDX2 induction (54.2% and 14.7%, respectively).